https://globalventuring.com/blog/2019/08/26/analysis-10x-genomics-files-for-100m-ipo/
Analysis: 10x Genomics files for $100m IPO - Global Venturing
Aug 28, 2019 - SoftBank-backed genome medical research tech provider 10x Genomics, previously backed by SoftBank, filed to go public. This may be a notable exit in burgeoning...
10x genomicsanalysisfiles100m
https://www.panabee.com/idea/is-10x-genomics-txg-a-buy-11212025
Is 10x Genomics (TXG) a Buy? | Nov 21 2025
Is 10x Genomics (TXG) a Buy? | Nov 21 2025: 10x Genomics (TXG) dominates single-cell/spatial biology but faces a "capital equipment freeze," causing instrument...
10x genomicstxgbuynov
https://www.panabee.com/company/TXG
10x Genomics Earnings & News | TXG
Earnings, news, dividends, and more for 10x Genomics (TXG). Beyond trending topics, investors can deepen their understanding of 10x Genomics with stock...
10x genomicsearnings newstxg
https://claude.com/connectors/10x-genomics-cloud
10x Genomics Cloud | Claude
Interact with 10x Genomics Cloud platform
10x genomicscloudclaude
https://www.bio-active.co.th/product-category/ngs-micro-array/10x-genomics/
10x GENOMICS Archives - www.bio-active.co.th
10x genomicsbio activearchiveswwwco
https://www.scdiscoveries.com/
Single Cell Sequencing CRO - 10X Genomics - Visium HD - DRUG-seq
Apr 22, 2026 - We are the only transcriptomics CRO that delivers high-quality data quickly and reliably. We are technology-agnostic and scientist-led.
single cell sequencing10x genomicsvisium hd
https://forexby.com/instruments/stocks/10x-genomics/
10X Genomics | Forexby
Apr 7, 2026 - 10X Genomics | Forexby
10x genomicsforexby
https://www.greatplacetowork.com/certified-company/7023648
Working at 10x Genomics | Great Place To Work®
Is 10x Genomics a great place to work for?
working at10x genomicsgreat place
https://www.insidermonkey.com/blog/barclays-turns-more-bullish-on-10x-genomics-inc-txg-despite-uneven-research-spending-1664532/
Barclays Turns More Bullish on 10x Genomics, Inc. (TXG) Despite Uneven Research Spending - Insider...
Dec 23, 2025 - On December 15, 2025, Barclays analyst Luke Sergott raised the price target for TXG from $17 to $22 while maintaining an Overweight rating, reflecting...